ATE362924T1 - N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung - Google Patents

N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung

Info

Publication number: ATE362924T1
Authority: AT; Austria
Prior art keywords: compound; methyl; production; active ingredient; phenylarylsulfonamide
Prior art date: 2001-03-12

Application number

AT02705096T

Other languages

English (en)

Inventor

Atsushi Naganawa

Kaoru Kobayashi

Takayuki Maruyama

Original Assignee

Ono Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-12

Filing date

2002-03-11

Publication date

2007-06-15

2002-03-11 Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co

2007-06-15 Application granted granted Critical

2007-06-15 Publication of ATE362924T1 publication Critical patent/ATE362924T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 6
238000000034 method Methods 0.000 title abstract 2
239000004480 active ingredient Substances 0.000 title 1
229940126601 medicinal product Drugs 0.000 title 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
-1 5-methyl-2-furyl Chemical group 0.000 abstract 1
206010036018 Pollakiuria Diseases 0.000 abstract 1
102000008866 Prostaglandin E receptors Human genes 0.000 abstract 1
108010088540 Prostaglandin E receptors Proteins 0.000 abstract 1
208000026723 Urinary tract disease Diseases 0.000 abstract 1
208000012931 Urologic disease Diseases 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
229940034982 antineoplastic agent Drugs 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
239000002221 antipyretic Substances 0.000 abstract 1
229940125716 antipyretic agent Drugs 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
230000027939 micturition Effects 0.000 abstract 1
125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
125000004076 pyridyl group Chemical group 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1
125000000335 thiazolyl group Chemical group 0.000 abstract 1
208000014001 urinary system disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Furan Compounds (AREA)

AT02705096T 2001-03-12 2002-03-11 N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung ATE362924T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2001068498		2001-03-12
JP2001281569		2001-09-17
JP2002007760		2002-01-16

Publications (1)

Publication Number	Publication Date
ATE362924T1 true ATE362924T1 (de)	2007-06-15

Family

ID=27346214

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT05109059T ATE522513T1 (de)	2001-03-12	2002-03-11	N-phenylarylsulfonamidverbindung, arzneimittel das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung
AT02705096T ATE362924T1 (de)	2001-03-12	2002-03-11	N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT05109059T ATE522513T1 (de)	2001-03-12	2002-03-11	N-phenylarylsulfonamidverbindung, arzneimittel das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung

Country Status (24)

Country	Link
US (3)	US7235667B2 (de)
EP (2)	EP1612208B1 (de)
JP (3)	JP3555620B2 (de)
KR (1)	KR100886854B1 (de)
CN (1)	CN1294126C (de)
AT (2)	ATE522513T1 (de)
AU (1)	AU2002238855B2 (de)
BR (1)	BR0208027A (de)
CA (1)	CA2439604C (de)
CZ (1)	CZ304035B6 (de)
DE (1)	DE60220255T2 (de)
DK (2)	DK1369419T3 (de)
ES (1)	ES2286230T3 (de)
HU (1)	HU230056B1 (de)
IL (2)	IL157701A0 (de)
MX (1)	MXPA03008134A (de)
NO (1)	NO329682B1 (de)
NZ (1)	NZ528120A (de)
PL (1)	PL218750B1 (de)
PT (2)	PT1369419E (de)
RU (1)	RU2299202C2 (de)
TW (1)	TWI317359B (de)
WO (1)	WO2002072564A1 (de)
ZA (1)	ZA200306884B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003264388A1 (en) *	2002-09-09	2004-03-29	Ono Pharmaceutical Co., Ltd.	Process for producing 4-methyl-1,3-thiazol-2-ylsulfonyl halide
DK1603893T3 (da) *	2003-01-29	2008-09-08	Asterand Uk Ltd	EP4 -Receptorantagonister
GB0317500D0 (en) *	2003-07-25	2003-08-27	Pfizer Ltd	Treatment of bph
EP1642594A1 (de) *	2003-06-27	2006-04-05	Ono Pharmaceutical Co., Ltd.	Mittel zur behandlung von harnwegserkrankungen
GB0401334D0 (en) *	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
US20080033018A1 (en) *	2004-07-05	2008-02-07	Chugai Seiyaku Kabushiki Kaisha	Therapeutic Agents For Overactive Bladder
JP2008189549A (ja) *	2005-05-12	2008-08-21	Astellas Pharma Inc	カルボン酸誘導体またはその塩
JP2009057282A (ja) *	2005-12-19	2009-03-19	Astellas Pharma Inc	カルボン酸誘導体又はその塩
TW200817319A (en) *	2006-08-10	2008-04-16	Astellas Pharma Inc	Sulfonamide compound or salt thereof
EP2123273B1 (de)	2007-02-16	2013-10-23	ONO Pharmaceutical Co., Ltd.	Therapeutisches mittel gegen harnausscheidungsstörungen
EP2177512B1 (de) *	2007-08-01	2012-04-18	Taisho Pharmaceutical Co., Ltd.	Hemmer der s1p1-bindung
SG176464A1 (en)	2008-05-09	2011-12-29	Agency Science Tech & Res	Diagnosis and treatment of kawasaki disease
EP2305641A4 (de) *	2008-06-23	2012-08-22	Astellas Pharma Inc	Sulfonamidverbindung oder salz daraus
TW201107309A (en) *	2009-07-27	2011-03-01	Kissei Pharmaceutical	Indole derivatives, or the pharmaceutically acceptable salts
JP2013532688A (ja)	2010-07-26	2013-08-19	ブリストル−マイヤーズスクイブカンパニー	Ｃｙｐ１７阻害剤として有用なスルホンアミド化合物
JP5363636B2 (ja) *	2011-10-21	2013-12-11	ファイザー・リミテッド	新規な塩および医学的使用
US20140039004A1 (en) *	2012-07-31	2014-02-06	Ono Pharmaceutical Co., Ltd.	Method of treating of gastroesophageal reflux disease
PT3138633T (pt) *	2014-04-30	2019-02-01	Ind Penalver Sl	Cabeça concêntrica programável para aplicação de líquido em tampas de diferentes formatos
EP3375782B1 (de) *	2015-11-13	2020-07-29	Daewoong Pharmaceutical Co., Ltd.	Natriumkanalblocker
RU2659955C1 (ru) *	2017-10-26	2018-07-04	Галина Ильхамовна Лукина	Способ диагностики высоких гастроэзофагеальных рефлюксов

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5748534B2 (de) *	1974-03-04	1982-10-16
DE2419923A1 (de) *	1973-04-28	1974-11-28	Fujisawa Pharmaceutical Co	Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel
DE2555048A1 (de) *	1975-12-06	1977-06-30	Pfersee Chem Fab	Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen
JPS5293469A (en) *	1976-02-02	1977-08-05	Fuji Photo Film Co Ltd	Method of curing gelatin
JPH05293469A (ja)	1992-04-17	1993-11-09	Toda Constr Co Ltd	滅菌精製水の製造方法およびその装置
NZ247440A (en) *	1992-05-06	1995-04-27	Squibb & Sons Inc	Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
TW523506B (en)	1996-12-18	2003-03-11	Ono Pharmaceutical Co	Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
WO2000069465A1 (en) *	1999-05-12	2000-11-23	Ono Pharmaceutical Co., Ltd.	Anticancer agents containing ep1 antagonists as the active ingredient
KR20020012639A (ko)	1999-07-29	2002-02-19	우에노 도시오	술폰아미드 유도체 및 알로디니아 치료제
CA2440374A1 (en)	2001-03-14	2002-09-19	Takayuki Maruyama	A pharmaceutical composition for the treatment of depression comprising the ep1 antagonist as active ingredient

2002
- 2002-03-11 NZ NZ528120A patent/NZ528120A/en not_active IP Right Cessation
- 2002-03-11 KR KR1020037011921A patent/KR100886854B1/ko not_active Expired - Fee Related
- 2002-03-11 ES ES02705096T patent/ES2286230T3/es not_active Expired - Lifetime
- 2002-03-11 WO PCT/JP2002/002245 patent/WO2002072564A1/ja not_active Ceased
- 2002-03-11 AU AU2002238855A patent/AU2002238855B2/en not_active Ceased
- 2002-03-11 CZ CZ20032452A patent/CZ304035B6/cs not_active IP Right Cessation
- 2002-03-11 BR BR0208027-3A patent/BR0208027A/pt not_active IP Right Cessation
- 2002-03-11 RU RU2003127677/04A patent/RU2299202C2/ru not_active IP Right Cessation
- 2002-03-11 HU HU0400155A patent/HU230056B1/hu not_active IP Right Cessation
- 2002-03-11 PL PL365100A patent/PL218750B1/pl unknown
- 2002-03-11 EP EP05109059A patent/EP1612208B1/de not_active Expired - Lifetime
- 2002-03-11 DK DK02705096T patent/DK1369419T3/da active
- 2002-03-11 DK DK05109059.5T patent/DK1612208T3/da active
- 2002-03-11 PT PT02705096T patent/PT1369419E/pt unknown
- 2002-03-11 PT PT05109059T patent/PT1612208E/pt unknown
- 2002-03-11 DE DE60220255T patent/DE60220255T2/de not_active Expired - Lifetime
- 2002-03-11 AT AT05109059T patent/ATE522513T1/de active
- 2002-03-11 US US10/471,673 patent/US7235667B2/en not_active Expired - Fee Related
- 2002-03-11 IL IL15770102A patent/IL157701A0/xx unknown
- 2002-03-11 AT AT02705096T patent/ATE362924T1/de active
- 2002-03-11 TW TW091104451A patent/TWI317359B/zh not_active IP Right Cessation
- 2002-03-11 MX MXPA03008134A patent/MXPA03008134A/es active IP Right Grant
- 2002-03-11 CA CA2439604A patent/CA2439604C/en not_active Expired - Fee Related
- 2002-03-11 JP JP2002571480A patent/JP3555620B2/ja not_active Expired - Fee Related
- 2002-03-11 CN CNB028097904A patent/CN1294126C/zh not_active Expired - Fee Related
- 2002-03-11 EP EP02705096A patent/EP1369419B1/de not_active Expired - Lifetime
2003
- 2003-09-02 IL IL157701A patent/IL157701A/en not_active IP Right Cessation
- 2003-09-03 ZA ZA2003/06884A patent/ZA200306884B/en unknown
- 2003-09-10 NO NO20034007A patent/NO329682B1/no not_active IP Right Cessation
- 2003-12-24 JP JP2003427226A patent/JP3741120B2/ja not_active Expired - Fee Related
2005
- 2005-08-26 JP JP2005245763A patent/JP4432051B2/ja not_active Expired - Fee Related
- 2005-09-30 US US11/239,406 patent/US7629369B2/en not_active Expired - Fee Related
2009
- 2009-10-21 US US12/603,194 patent/US8088802B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7629369B2 (en)	2009-12-08
JP2004149545A (ja)	2004-05-27
PT1369419E (pt)	2007-08-16
NO329682B1 (no)	2010-11-29
HUP0400155A3 (en)	2007-05-02
DE60220255D1 (de)	2007-07-05
NO20034007D0 (no)	2003-09-10
HUP0400155A2 (hu)	2004-08-30
ATE522513T1 (de)	2011-09-15
DE60220255T2 (de)	2008-01-17
US20100041708A1 (en)	2010-02-18
NO20034007L (no)	2003-11-12
NZ528120A (en)	2006-05-26
CZ304035B6 (cs)	2013-08-28
DK1612208T3 (da)	2011-12-12
EP1612208B1 (de)	2011-08-31
CZ20032452A3 (cs)	2003-11-12
PL365100A1 (en)	2004-12-27
RU2299202C2 (ru)	2007-05-20
ZA200306884B (en)	2005-03-30
CN1294126C (zh)	2007-01-10
JP4432051B2 (ja)	2010-03-17
KR20030082978A (ko)	2003-10-23
EP1369419A1 (de)	2003-12-10
CA2439604C (en)	2012-05-01
JP2006028193A (ja)	2006-02-02
PL218750B1 (pl)	2015-01-30
IL157701A0 (en)	2004-03-28
US8088802B2 (en)	2012-01-03
AU2002238855B2 (en)	2007-12-06
TWI317359B (en)	2009-11-21
US20050124672A1 (en)	2005-06-09
MXPA03008134A (es)	2004-03-10
IL157701A (en)	2010-06-30
BR0208027A (pt)	2004-12-28
WO2002072564A1 (en)	2002-09-19
EP1612208A3 (de)	2006-12-06
KR100886854B1 (ko)	2009-03-05
JPWO2002072564A1 (ja)	2004-07-02
PT1612208E (pt)	2011-10-12
JP3741120B2 (ja)	2006-02-01
RU2003127677A (ru)	2005-03-27
CN1509278A (zh)	2004-06-30
US7235667B2 (en)	2007-06-26
HU230056B1 (hu)	2015-06-29
DK1369419T3 (da)	2007-09-24
US20060030713A1 (en)	2006-02-09
CA2439604A1 (en)	2002-09-19
EP1612208A2 (de)	2006-01-04
EP1369419B1 (de)	2007-05-23
ES2286230T3 (es)	2007-12-01
EP1369419A4 (de)	2005-03-16
JP3555620B2 (ja)	2004-08-18

Legal Events

Date

Code

Title

Description

2007-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1369419

Country of ref document: EP

Publication	Publication Date	Title
ATE522513T1 (de)	2011-09-15	N-phenylarylsulfonamidverbindung, arzneimittel das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung
DE60018064D1 (de)	2005-03-17	Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar)
MY143051A (en)	2011-02-28	Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
NZ514661A (en)	2003-06-30	alpha-substituted carboxylic acid derivatives and their use as therapeutic agents in pharmaceutical compositions
GEP20084325B (en)	2008-03-25	Purine compounds and uses thereof as cannabinoid receptor ligandspurine compounds and uses thereof as cannabinoid receptor ligands
BR0014679A (pt)	2002-07-02	2-tio-3,5-diciano-4-aril-6-aminopiridinas substituìdas e sua aplicação
ES2195943T3 (es)	2003-12-16	Compuestos heteroaromaticos biciclicos y triciclicos.
DE60021113T2 (de)	2006-06-01	Albumin-bindende verbindungen die die nichtenzymatische glycosylierung verhindern und die zur behandlung von glycosylierungsbedingten erkrankungen verwendet werden können
DE60039878D1 (de)	2008-09-25	XENON ALS NMDA-ANTOGONIST zur Neuroprotektion
KR970701698A (ko)	1997-04-12	프로스타글란딘 i₂작용물질로서의 나프탈렌 유도체(naphthalene derivatives as prostaglandin i₂agonists)
HK1046405A1 (zh)	2003-01-10	作为nmda受体拮抗剂用於治疗疼痛的取代的1，5-二氢吡咯-2-酮衍生物
ATE246180T1 (de)	2003-08-15	Benzofuranon-derivate und verfahren zu ihrer herstellung
DE59905075D1 (de)	2003-05-22	S-substituierte 11beta-benzaldoxim-estra-4,9-dien-kohlensäurethiolester, verfahren zu deren herstellung und diese verbindungen enthaltene pharmazeutische zubereitungen
WO2007127421A3 (en)	2008-01-24	Process for the synthesis of (+) and (-)-1-aryl-3-azabicyclo[3.1.0]hexanes
JPS58159489A (ja)	1983-09-21	２，３−ジアリ−ル−５−ハロチオフエン化合物
WO2003018010A1 (en)	2003-03-06	Preventive and/or remedial agent for disease attributable to arteriosclerotic activity
Breining et al.	2005	Neuronal nicotinic acetylcholine receptor modulators: recent advances and therapeutic potential
WO2001082858A2 (de)	2001-11-08	Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen
DE50006842D1 (de)	2004-07-22	4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung
JP5439817B2 (ja)	2014-03-12	尿排出障害治療剤
WO2002044130A1 (fr)	2002-06-06	Dérivés d'acide carboxylique substitués
JPWO2001032164A1 (ja)	2003-05-20	２０−ｈｅｔｅ産生酵素阻害剤
EP1869004A4 (de)	2010-08-25	Substituierte carbonsäurederivate zur behandlung von diabetes und lipidstörungen, ihre herstellung und anwendung
ATE247963T1 (de)	2003-09-15	Medikament zur behandlung von glaukoma und ischämischer retinopathie
CA3305394A1 (en)	2026-04-10	Irak degradation agent and use thereof